Company news
Supernus Pharmaceuticals, Inc. news in 2025
Supernus Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
December 2, 2025
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
November 11, 2025
Supernus Announces Third Quarter 2025 Financial Results
November 3, 2025
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 20, 2025
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025
Supernus Pharmaceuticals to Participate in September Investor Conferences
August 26, 2025
Supernus Announces Second Quarter 2025 Financial Results
August 4, 2025
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
July 30, 2025
Sage Therapeutics Announces Second Quarter 2025 Financial Results
July 30, 2025
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 27, 2025
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
July 21, 2025
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
June 15, 2025
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
May 28, 2025
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
May 27, 2025
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
May 27, 2025
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
May 19, 2025
Supernus Announces First Quarter 2025 Financial Results
May 5, 2025
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
April 22, 2025
Supernus to Participate in Two Upcoming Investor Conferences
March 3, 2025
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
February 24, 2025
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
February 17, 2025
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
February 3, 2025
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
January 26, 2025
Calls in 2025
- Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2025 Earnings Call
Nov 4, 2025
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2025 Earnings Call
Aug 5, 2025
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2025 Earnings Call
May 6, 2025
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2024 Earnings Call
Feb 25, 2025
Transcript
Decks in 2025
- Merger or Acquisition (June 2025)
Merger or acquisition · 16 slides · Jun 16, 2025
- Q1 2025 Earnings Presentation
Earnings · 32 slides · May 6, 2025